Physician profile
Marikit Beth Smith
NPI 1659983195
$2,874.55
in general payments reported to CMS, 2019-2025
25 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $500 · 2022: $612 · 2023: $338 · 2024: $1,042 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $623.28 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $324.65 | 2021-2022 | |
| Axsome Therapeutics, INC. | $308.88 | 2023-2024 | Auvelity |
| Allergan, INC. | $301.79 | 2021 | |
| Lilly USA, LLC | $167.30 | 2021-2024 | Mounjaro, Jardiance |
| Abbvie INC. | $130.73 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.97 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.26 | 2021-2022 | |
| Novo Nordisk INC | $104.70 | 2021-2024 | Wegovy |
| Shield Therapeutics INC | $96.97 | 2023-2024 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $90.58 | 2022-2023 | Seglentis, Livalo |
| Pfizer INC. | $86.99 | 2022-2024 | |
| Mannkind Corporation | $60.43 | 2022-2023 | Afrezza |
| Merck Sharp & Dohme LLC | $51.56 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $43.83 | 2024 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $34.39 | 2021-2023 | Sohonos |
| Amgen INC. | $34.36 | 2024 | Repatha, Otezla |
| Seqirus USA INC | $29.30 | 2024 | Flucelvax, Fluad |
| Abiomed | $27.78 | 2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $24.01 | 2022 | |
| Exact Sciences Corporation | $20.86 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $19.50 | 2024 | Voquezna |
| Eisai INC. | $19.42 | 2021 | |
| Amarin Pharma, INC. | $18.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marikit Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.